Publication Cover
Hemoglobin
international journal for hemoglobin research
Volume 45, 2021 - Issue 4
116
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

High Systolic Blood Pressure, Anterior Segment Changes and Visual Impairment Independently Predict Sickle Cell Retinopathy

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, , , , ORCID Icon, ORCID Icon, , ORCID Icon, & show all
Pages 228-233 | Received 04 May 2021, Accepted 22 Jun 2021, Published online: 06 Aug 2021

References

  • Steinberg MH. Predicting clinical severity in sickle cell anaemia. Br J Haematol. 2005;129(4):465–481.
  • Ballas SK, Lieff S, Benjamin LJ, et al. Comprehensive sickle cell centers. Definitions of the phenotypic manifestations of sickle cell disease. Am J Hematol. 2010;85(1):6–13.
  • Abdalla Elsayed MEA, Mura M, Al Dhibi H, et al. Sickle cell retinopathy. A focused review. Graefes Arch Clin Exp Ophthalmol. 2019;257(7):1353–1364.
  • Shukla P, Verma H, Patel S, et al. Ocular manifestations of sickle cell disease and genetic susceptibility for refractive errors. Taiwan J Ophthalmol. 2017;11(2):89–93.
  • Eruchalu UV, Pam VA, Akuse RM. Ocular findings in children with severe clinical symptoms of homozygous sickle cell anaemia in Kaduna, Nigeria. West Afr J Med. 2006;25(2):88–91.
  • Ogedegbe G, Pickering T. Principles and techniques of blood pressure measurement. Cardiol Clin. 2010;28(4):571–586.
  • Dandona L, Dandona R. Revision of visual impairment definitions in the International Statistical Classification of Diseases. BMC Med. 2006;4:7.
  • Goldberg MF. Classification and pathogenesis of proliferative sickle retinopathy. Am J Ophthalmol. 1971;71(3):649–665.
  • Galadanci NA, Abdullahi SU, Ali Abubakar S, et al. Moderate fixed-dose hydroxyurea for primary prevention of strokes in Nigerian children with sickle cell disease: final results of the SPIN trial. Am J Hematol. 2020;95(9):E247–E250.
  • Galadanci NA, Abdullahi SU, Vance LD, et al. Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial). Am J Hematol. 2017;92(8):780–788.
  • Sonubi O, Kotila TR. Knowledge, attitude and use of hydroxuyrea among adult sickle cell disease patients. Ann Ib Postgrad Med. 2019;17(2):153–156.
  • Akingbola TS, Tayo BO, Salako B, et al. Comparison of patients from Nigeria and the USA highlights modifiable risk factors for sickle cell anemia complications. Hemoglobin. 2014;38(4):236–243.
  • Kaimbo Wa Kaimbo D, Ngiyulu Makuala R, Dralands L, et al. Ocular findings in children with homozygous sickle cell disease in the Democratic Republic of Congo. Bull Soc Belge Ophtalmol. 2000;275:27–30.
  • Hayes RJ, Condon PI, Serjeant GR. Haematological factors associated with proliferative retinopathy in homozygous sickle cell disease. Br J Ophthalmol. 1981;65(1):29–35.
  • Obikili AG, Oji EO, Onwukeme KE. findings in homozygous sickle cell disease in Jos, Nigeria. Afr J Med Med Sci. 1990;19(4):245–250.
  • Elebesunu-Amadasu M, Okafor LA. Ocular manifestations of sickle cell disease in Nigerians; experience in Benin City, Nigeria. Trop Geogr Med. 1985;37(3):261–263.
  • Osafo-Kwaako A, Kimani K, Ilako D, et al. Ocular manifestations of sickle cell disease at the Korle-bu Hospital, Accra, Ghana. Eur J Ophthalmol. 2011;21(4):484–489.
  • Clarkson JG. The ocular manifestations of sickle cell disease: a prevalence and natural history study. Trans Am Ophthalmol Soc. 1992;90:482–504.
  • Kent D, Arya R, Aclimandos WA, et al. Screening for ophthalmic manifestations of sickle cell disease in the United Kingdom. Eye. 1994;8(6):618–622.
  • Rosenberg JB, Hutcheson KA. Pediatric sickle cell retinopathy: correlation with clinical factors. JAAPOS. 2011;15(1):49–53.
  • Nagpal KC, Patrianakos D, Asdourian GK, et al. Spontaneous regression (autoinfarction) of proliferative sickle retinopathy. Am J Ophthalmol. 1975;80(5):885–892.
  • Klein R, Klein BE, Moss SE. The relation of systemic hypertension to changes in the retinal vasculature: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc. 1997;95:329–250.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.